Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy.
H Azuma, M Oshima, K Ito, A Okuno… - European journal of …, 2000 - search.ebscohost.com
H Azuma, M Oshima, K Ito, A Okuno, I Kawabata, K Banba, H Murahashi, T Sekine, Y Kato…
European journal of pediatrics, 2000•search.ebscohost.comInterleukin-2 production may be one of the underlying causes of Wiskott-Aldrich syndrome
immunodeficiency and recombinant interleukin-2 administration (or an infusion of T-cells
expanded by CD3 stimulation and rIL-2) is able, to some extent, to restore defective T-cell
function.
immunodeficiency and recombinant interleukin-2 administration (or an infusion of T-cells
expanded by CD3 stimulation and rIL-2) is able, to some extent, to restore defective T-cell
function.
Abstract
Interleukin-2 production may be one of the underlying causes of Wiskott-Aldrich syndrome immunodeficiency and recombinant interleukin-2 administration (or an infusion of T-cells expanded by CD3 stimulation and rIL-2) is able, to some extent, to restore defective T-cell function.
search.ebscohost.com